Johnson & Johnson reported robust first-quarter results with revenue reaching $24.1 billion (a 9.9% year-over-year increase) and an adjusted EPS of $2.70, beating consensus estimates. Primary drivers included double-digit operational growth in the Innovative Medicine segment, anchored by oncology assets like Darzalex and Carvykti, alongside solid 4.6% operational growth in MedTech led by cardiovascular products, which successfully offset an expected sharp decline in Stelara sales due to biosimilar competition.
Note: Johnson & Johnson's FY'25 ended on December 28, 2025. Q1 FY'26 ended on March 29, 2026.
The company continues to integrate recent multibillion-dollar acquisitions within its MedTech segment to bolster its cardiovascular offerings. This strategic pivot focuses on high-growth markets such as intravascular lithotripsy and heart recovery, aiming to offset potential revenue gaps created by upcoming patent expirations in the pharmaceutical portfolio.
Below are key drivers of Johnson & Johnson's value that present opportunities for upside or downside to the current Trefis price estimate:
For additional details, select a division from the interactive Trefis split for Johnson & Johnson at the top of the page.
Johnson & Johnson operates as a diversified healthcare giant engaged in the research, development, and commercialization of a broad range of products, focusing strictly on its Innovative Medicine and MedTech segments following the separation of its consumer health business.
The Innovative Medicine segment is the primary value driver for the company due to its high-margin specialty pharmaceuticals.
The company holds a commanding market share in the treatment of multiple myeloma, anchored by its blockbuster drug Darzalex. The extensive clinical data and established physician familiarity create a substantial barrier to entry for competitors in this space.
The MedTech division benefits from a massive global installed base of surgical and interventional equipment. This ecosystem generates reliable recurring revenue through consumables, servicing, and long-term hospital contracts, providing a stable cash flow moat.
The pharmaceutical industry is facing a major wave of patent cliffs, and Johnson & Johnson is navigating the loss of exclusivity for key biologic drugs. The introduction of biosimilars will inevitably compress pricing power and necessitate a rapid pivot toward next-generation therapies.
To counter organic growth deceleration, the company strategy relies heavily on targeted mergers and acquisitions. By deploying its significant cash reserves to acquire specialized medical technology and clinical-stage biotech firms, the company is actively reshaping its revenue base for the next decade.
